1 / 16

Global Human Insulin Market to 2020

Diabetes refers to a group of metabolic disease characterized by high blood sugar level. It occurs due to inadequate secretion of insulin inside the pancreas. Some of the common symptoms for diabetes are frequent urination, excessive thirst, increased hunger, weight loss and tiredness. Type 1, type 2 and gestational diabetes are three common types of diabetes.

addiethomes
Télécharger la présentation

Global Human Insulin Market to 2020

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry PacifictoWitnessfastestGrowthby2020 : Asia PersistenceMarketResearch HumanInsulinMarketWillReach US$49,197.3millionin2020:Persistence MarketResearch 1 PersistenceMarketResearch

  2. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 PersistenceMarketResearchReleasedNewMarketReport“GlobalMarketStudyonHuman Insulin:AsiaPacifictoWitnessfastestGrowthby2020,”theglobalhumaninsulin marketwasvaluedatUSD24,332.6millionin2014andwasexpectedtogrowataCAGRof 12.4%from2014to2020,toreachanestimatedvalueofUSD49,197.3millionin2020. BrowsethefullGlobalMarketStudyonHumanInsulin:AsiaPacifictoWitnessfastestGrowth by 2020 report at http://www.persistencemarketresearch.com/market- research/human-insulin-market.asp Globally,thehumaninsulinmarketiswitnessingsignificantgrowthduetoincreasing prevalenceofdiabetesandincreasingawarenessamongpeopleaboutdiabetescare.In addition,technologicaladvancementsininsulindeliverydevicesandincreasingprevalenceof lifestylerelateddisorderssuchasobesityarealsodrivingthegrowthofthemarket.However, unevenpricingandlimitedaccesstohumaninsulininemergingcountriessuchasBrazil,India, andChinaareinhibitingthegrowthofthehumaninsulinmarket.Inaddition,strictregulatory requirementsfordrugapprovalarealsorestrainingthegrowthofthemarket.Theglobal humaninsulinmarketwasanticipatedtogrowfromanestimatedUSD24,332.6millionin2014 toUSD49,197.3millionin2020ataCAGRof12.4%duringtheforecastperiod. InNorthAmerica,increasingprevalenceofdiabeteswithgrowingageandavailabilityof advancedhumaninsulininfusiondevicesaredrivingtheuseofhumaninsulininthemarket. Inaddition,increasingprevalenceoflifestyleassociateddisorderssuchasobesityisalso boostingthegrowthofthehumaninsulinmarketinthisregion.Forinstance,accordingtothe CentersforDiseasesControlandPrevention(CDC),aU.S.-basednationalpublichealth institute,overone-thirdchildrenandadolescentswereobesein2012intheU.S. InEurope,thehumaninsulinmarketisdrivenbyrisingagingpopulationandincreasing prevalenceofdiabetes.Inaddition,inGermanythemarketisevolvingduetorisingprevalence ofdiabetesandincreasingawarenessamongpeopleaboutdiabetescare.However,inAsia- Pacificthegrowthforhumaninsulinismuchhigherthandevelopedcountriesduetoincreasing prevalenceofdiabetesandincreasinggovernmentinitiativesforimprovinghealthcare. NovoNordiskA/S,EliLillyandCompany,Sanofi,Biocon,TonghuaDongbaoPharmaceuticalCo., Ltd.,Adocia,Merck&Co.,Inc.,Pfizer,Inc.,Wockhardt,Julphar,Bristol-MyersSquibbCompany, GlaxoSmithKlinePlcandOramedPharmaceuticals,Inc.aresomeofthemajorplayersinhuman insulinmarket. 2 PersistenceMarketResearch

  3. HumanInsulinMarket-GlobalStudyonHuman PacifictoWitnessfastestGrowthby2020 Insulin Industry : Asia Thehumaninsulinmarketissegmentedasfollows: Humaninsulinmarket,bytype •Traditionalhumaninsulin •Modernhumaninsulin Traditionalhumaninsulinmarket,bytype •Shortactinghumaninsulin •Intermediateactinghumaninsulin •Premixedhumaninsulin Modernhumaninsulinmarket,bytype •Rapid-actinghumaninsulin •Long-actinghumaninsulin •Premixedhumaninsulin Humaninsulinmarket,bydisease •Type1diabetes •Type2diabetes Traditionalhumaninsulinmarket,bybrand •Humulin •Insuman •Others Modernhumaninsulinmarket,bybrand •Lantus •Novolog •Humalog •Levemir 3 PersistenceMarketResearch

  4. HumanInsulinMarket-GlobalStudyon PacifictoWitnessfastestGrowthby2020 Human Insulin Industry : Asia •Novomix •Apidra •Others Humaninsulinmarket,bygeography •NorthAmerica •TheU.S. •Canada •Europe •Germany •France •TheU.K. •Asia-Pacific •Japan •China •India •RestoftheWorld(RoW) MarketHistory: Globally,thehumaninsulinmarket iswitnessing significant growthdueto increasing prevalence of diabetesandobesity.Inaddition,increasingR&Dinvestmentsindrugdiscoveryanddevelopmentand risingawarenessaboutdiabetesarealsodrivingthegrowthofthemarket.However,unevenpricingand limitedaccesstohumaninsulininemergingcountriesandstrictregulatoryrequirementfordrugapproval inhibitsthegrowthofthemarket.Theglobalhumaninsulinmarketwasanticipatedtogrowfroman estimatedUSD24,332.6millionin2014toUSD49,197.3millionby2020ataCAGRof12.4%duringthe forecastperiod. NorthAmericahasthelargestmarketandAsia-Pacifichasthefastestgrowingmarketforhumaninsulin. Intermsoftypeofhumaninsulin,modernhumaninsulinrepresentsthelargestandfastestgrowingsegmentofthismarket. Modernhumaninsulinprovideseffectiveresultscomparetotraditionalhumaninsulin.Dosagesand durationofmodernhumaninsulinvaryfrompersontoperson,asinsulinrequirementdiffersfromperson 4 PersistenceMarketResearch

  5. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 toperson.ModernhumaninsulinwasestimatedatUSD19,526.8millionin2014andwasexpectedto reachUSD40,987.1millionby2020,growingataCAGRof13.2%duringtheforecastperiod. SomeofthemajorplayersinthehumaninsulinmarketareNovoNordiskA/S,EliLillyandCompany, Sanofi,Biocon,Tonghua Wockhardtandothers. Dongbao Pharmaceutical Co., Ltd.,Adocia, Merck & Co., Inc., Pfizer, Inc., TableofContent Chapter1Preface 1.1ReportDescription 1.2ResearchMethodology 1.3Assumptions Chapter2MarketSynopsis Chapter3Porter’sFiveForcesAnalysis 3.1BargainingPowerofSuppliers 3.2BargainingPowerofBuyers 3.3ThreatofNewEntrants 3.4ThreatofSubstitutes 3.5IntensityofRivalry 5 PersistenceMarketResearch

  6. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry PacifictoWitnessfastestGrowthby2020 : Asia Chapter4IndustryOverview 4.1MarketDefinition 4.2MarketDrivers 4.2.1Growingprevalenceofdiabetes 4.2.2Technologicaladvancementsinhumaninsulindeliverydevices 4.2.3Increasingawarenessamongpeopletowardsdiabetescare 4.3ImpactAnalysisofMarketDrivers 4.4MarketRestraints 4.4.1Unevenpricingandlimitedaccesstohumaninsulininemergingcountries 4.4.2Strictregulatoryrequirementsfordrugapproval 4.5ImpactAnalysisofMarketRestraints 4.6MarketTrends 4.6.1Increasingusageofinsulinpensforadministrationofhumaninsulin Chapter5GlobalMarketSizeandForecast Chapter6MarketSizeandForecastbyType 6.1TraditionalHumanInsulin 6.2ModernHumanInsulin Chapter7MarketSizeandForecastofTraditionalHumanInsulinbyType 7.1Short-actingHumanInsulin 7.2Intermediate-actingHumanInsulin 7.3PremixedHumanInsulin Chapter8MarketSizeandForecastofModernHumanInsulinbyType 8.1Rapid-actingHumanInsulin 8.2Long-actingHumanInsulin 8.3PremixedHumanInsulin Chapter9MarketSizeandForecastbyDisease 6 PersistenceMarketResearch

  7. HumanInsulinMarket-GlobalStudyonHuman PacifictoWitnessfastestGrowthby2020 Insulin Industry : Asia 9.1Type1Diabetes 9.2Type2Diabetes Chapter10MarketSizeandForecastbyBrand 10.1TraditionalHumanInsulinBrand 10.2ModernHumanInsulinBrand Chapter11MarketSizeandForecastbyGeography 11.1NorthAmerica 11.1.1ScenariointheU.S. 11.1.2ScenarioinCanada 11.2Europe 11.2.1ScenarioinGermany 11.2.2ScenarioinFrance 11.2.3ScenariointheU.K. 11.3AsiaPacific 11.3.1ScenarioinJapan 11.3.2ScenarioinChina 11.3.3ScenarioinIndia Chapter12PipelineDrugsforDiabetesTreatment 12.1DrugsUnderDevelopmentforDiabetesTreatment Chapter13CompetitiveScenario 13.1CompetitiveBenchmarking Chapter14CompanyProfiles 14.1NovoNordiskA/S 14.1.1Companyoverview 14.1.2Productsandservices 14.1.3Financialperformance 14.1.4Keydevelopments 7 PersistenceMarketResearch

  8. HumanInsulinMarket-GlobalStudyon PacifictoWitnessfastestGrowthby2020 Human Insulin Industry : Asia 14.2EliLillyandCompany 14.2.1Companyoverview 14.2.2Productsandservices 14.2.3Financialperformance 14.2.4Keydevelopments 14.3Sanofi 14.3.1Companyoverview 14.3.2Productsandservices 14.3.3Financialperformance 14.3.4Keydevelopments 14.4Biocon 14.4.1Companyoverview 14.4.2Productsandservices 14.4.3Financialperformance 14.4.4Keydevelopments 14.5TonghuaDongbaoPharmaceuticalCo.,Ltd. 14.5.1Companyoverview 14.5.2Productsandservices 14.5.3Financialperformance 14.5.4Keydevelopments 14.6ADOCIA 14.6.1Companyoverview 14.6.2Productsandservices 14.6.3Financialperformance 14.6.4Keydevelopments 14.7Wockhardt 14.7.1Companyoverview 14.7.2Productsandservices 14.7.3Financialperformance 14.7.4Keydevelopments 14.8Julphar 14.8.1Companyoverview 8 PersistenceMarketResearch

  9. HumanInsulinMarket-GlobalStudyon PacifictoWitnessfastestGrowthby2020 Human Insulin Industry : Asia 14.8.2Productsandservices 14.8.3Financialperformance 14.8.4Keydevelopments 14.9Merck&Co.,Inc. 14.9.1Companyoverview 14.9.2Productsandservices 14.9.3Financialperformance 14.9.4Keydevelopments 14.10Pfizer,Inc. 14.10.1Companyoverview 14.10.2Productsandservices 14.10.3Financialperformance 14.10.4Keydevelopments 14.11Bristol-MyersSquibbCompany 14.11.1Companyoverview 14.11.2Productsandservices 14.11.3Financialperformance 14.11.4Keydevelopments 14.12GlaxoSmithKlinePlc 14.12.1Companyoverview 14.12.2Productsandservices 14.12.3Financialperformance 14.12.4Keydevelopments 14.13OramedPharmaceuticals,Inc. 14.13.1Companyoverview 14.13.2Productsandservices 14.13.3Financialperformance 14.13.4Keydevelopments 9 PersistenceMarketResearch

  10. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 ListofTables TABLE1Marketsnapshot:Humaninsulinmarket,2014and2020 TABLE2Driversforhumaninsulinmarket:Impactanalysis TABLE3Restraintsforhumaninsulinmarket:Impactanalysis TABLE4Globalhumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE5Globalhumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE6Globalhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE7Globalhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE8Globaltraditionalhumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE9Globaltraditionalhumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE10Globalmodernhumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE11Globalmodernhumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE12Globalshort-actinghumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE13Globalshort-actinghumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE14Globalintermediate-actinghumaninsulinmarketsize,byregion,2010–2013(USD million) TABLE15Globalintermediate-actinghumaninsulinmarketsize,byregion,2014–2020(USD million) TABLE16Globalpremixedhumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE17Globalpremixedhumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE18Globalrapid-actinghumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE19Globalrapid-actinghumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE20Globallong-actinghumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE21Globallong-actinghumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE22Globalpremixedhumaninsulinmarketsize,byregion,2010–2013(USDmillion) TABLE23Globalpremixedhumaninsulinmarketsize,byregion,2014–2020(USDmillion) TABLE24Globaltype1diabeteshumaninsulinmarketsize,byregion,2010–2013(USD million) TABLE25Globaltype1diabeteshumaninsulinmarketsize,byregion,2014–2020(USD million) 10 PersistenceMarketResearch

  11. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 TABLE26Globaltype2diabeteshumaninsulinmarketsize,byregion,2010–2013(USD million) TABLE27Globaltype2diabeteshumaninsulinmarketsize,byregion,2014–2020(USD million) TABLE28Globaltraditionalhumaninsulinmarketsize,bybrand,2010–2013(USDmillion) TABLE29Globaltraditionalhumaninsulinmarketsize,bybrand,2014–2020(USDmillion) TABLE30Globalmodernhumaninsulinmarketsize,bybrand,2010–2013(USDmillion) TABLE31Globalmodernhumaninsulinmarketsize,bybrand,2014–2020(USDmillion) TABLE32TheNorthAmericanhumaninsulinmarketsize,bycountry,2010–2013(USD million) TABLE33TheNorthAmericanhumaninsulinmarketsize,bycountry,2014–2020(USD million) TABLE34TheU.S.humaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE35TheU.S.humaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE36TheU.S.traditionalhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE37TheU.S.traditionalhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE38TheU.S.modernhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE39TheU.S.modernhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE40TheCanadianhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE41TheCanadianhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE42TheCanadiantraditionalhumaninsulinmarketsize,bytype,2010–2013(USD million) TABLE43TheCanadiantraditionalhumaninsulinmarketsize,bytype,2014–2020(USD million) TABLE44TheCanadianmodernhumaninsulinmarketsize,bytype,2010–2013(USD million) TABLE45TheCanadianmodernhumaninsulinmarketsize,bytype,2014–2020(USD million) TABLE46TheEuropeanhumaninsulinmarketsize,bycountry,2010–2013(USDmillion) TABLE47TheEuropeanhumaninsulinmarketsize,bycountry,2014–2020(USDmillion) TABLE48TheGermanhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE49TheGermanhumaninsulinmarketsize,bytype,2014–2020(USDmillion) 11 PersistenceMarketResearch

  12. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 TABLE50TheGermantraditionalhumaninsulinmarketsize,bytype,2010–2013(USD million) TABLE51TheGermantraditionalhumaninsulinmarketsize,bytype,2014–2020(USD million) TABLE52TheGermanmodernhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE53TheGermanmodernhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE54TheFrenchhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE55TheFrenchhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE56TheFrenchtraditionalhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE57TheFrenchtraditionalhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE58TheFrenchmodernhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE59TheFrenchmodernhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE60TheU.K.humaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE61TheU.K.humaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE62TheU.K.traditionalhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE63TheU.K.traditionalhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE64TheU.K.modernhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE65TheU.K.modernhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE66TheAsiaPacifichumaninsulinmarketsize,bycountry,2010–2013(USDmillion) TABLE67TheAsiaPacifichumaninsulinmarketsize,bycountry,2014–2020(USDmillion) TABLE68TheJapanesehumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE69TheJapanesehumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE70TheJapanesetraditionalhumaninsulinmarketsize,bytype,2010–2013(USD million) TABLE71TheJapanesetraditionalhumaninsulinmarketsize,bytype,2014–2020(USD million) TABLE72TheJapanesemodernhumaninsulinmarketsize,bytype,2010–2013(USD million) TABLE73TheJapanesemodernhumaninsulinmarketsize,bytype,2014–2020(USD million) TABLE74TheChinesehumaninsulinmarketsize,bytype,2010–2013(USDmillion)TABLE75TheChinesehumaninsulinmarketsize,bytype,2014–2020(USDmillion) 12 PersistenceMarketResearch

  13. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 TABLE76TheChinesetraditionalhumaninsulinmarketsize,bytype,2010–2013(USD million) TABLE77TheChinesetraditionalhumaninsulinmarketsize,bytype,2014–2020(USD million) TABLE78TheChinesemodernhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE79TheChinesemodernhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE80TheIndianhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE81TheIndianhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE82TheIndiantraditionalhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE83TheIndiantraditionalhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE84TheIndianmodernhumaninsulinmarketsize,bytype,2010–2013(USDmillion) TABLE85TheIndianmodernhumaninsulinmarketsize,bytype,2014–2020(USDmillion) TABLE86Majorpipelinedrugsfordiabetestreatment TABLE87MajorproductsegmentsofNovoNordiskA/S TABLE88MajorproductsegmentsofEliLillyandCompany TABLE89MajorproductcategoriesofSanofi TABLE90MajorproductcategoriesofBiocon TABLE91MajorproductcategoriesofTonghuaDongbaoPharmaceuticalCo.,Ltd. TABLE92MajorproductcategoriesofAdocia TABLE93MajorproductcategoriesofWockhardt TABLE94MajorproductcategoriesofJulphar TABLE95MajorproductcategoriesofMerck&Co.,Inc. TABLE96MajorproductcategoriesofPfizer,Inc. TABLE97MajorproductcategoriesofBristol-MyersSquibbCompany TABLE98MajorproductcategoriesofGlaxoSmithKlinePlc TABLE99MajorproductcategoriesofOramedPharmaceuticals,Inc. ListofFigures FIG.1Humaninsulinmarket:Porter’sfiveforcesanalysis FIG.1Majortypesofhumaninsulin FIG.2Majortypesofinsulindeliverydevices 13 PersistenceMarketResearch

  14. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 FIG.3Numberofpeoplewithdiabetesmellitus(20–79years)inmajorcountries,2010and 2030(million) FIG.4Prevalenceofoverweightandobesemalesaged30yearsandabove,2005and2015 (%) FIG.5Prevalenceofoverweightandobesefemalesaged30yearsandabove,2005and2015 (%) FIG.6Globalhumaninsulinmarketshare,byregion,byvalue,2013 FIG.7Globalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.8Globaltraditionalhumaninsulinmarketshare,byregion,byvalue,2013 FIG.9Globalmodernhumaninsulinmarketshare,byregion,byvalue,2013 FIG.10Globalshort-actinghumaninsulinmarketshare,byregion,byvalue,2013 FIG.11Globalintermediate-actinghumaninsulinmarketshare,byregion,byvalue,2013 FIG.12Globalpremixedhumaninsulinmarketshare,byregion,byvalue,2013 FIG.13Globalrapid-actinghumaninsulinmarketshare,byregion,byvalue,2013 FIG.14Globallong-actinghumaninsulinmarketshare,byregion,byvalue,2013 FIG.15Globalpremixedhumaninsulinmarketshare,byregion,byvalue,2013 FIG.16Globaltype1diabeteshumaninsulinmarketshare,byregion,byvalue,2013 FIG.17Globaltype2diabeteshumaninsulinmarketshare,byregion,byvalue,2013 FIG.18Globaltraditionalhumaninsulinmarketshare,bybrand,byvalue,2013 FIG.19Globalmodernhumaninsulinmarketshare,bybrand,byvalue,2013 FIG.20TheNorthAmericanhumaninsulinmarketshare,bycountry,byvalue,2013 FIG.21TheU.S.humaninsulinmarketshare,bytype,byvalue,2013 FIG.22TheU.S.traditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.23TheU.S.modernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.24TheCanadianhumaninsulinmarketshare,bytype,byvalue,2013 FIG.25TheCanadiantraditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.26TheCanadianmodernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.27TheEuropeanhumaninsulinmarketshare,bycountry,byvalue,2013 FIG.28TheGermanhumaninsulinmarketshare,bytype,byvalue,2013 FIG.29TheGermantraditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.30TheGermanmodernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.31TheFrenchhumaninsulinmarketshare,bytype,byvalue,2013 14 PersistenceMarketResearch

  15. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 FIG.32TheFrenchtraditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.33TheFrenchmodernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.34TheU.K.humaninsulinmarketshare,bytype,byvalue,2013 FIG.35TheU.K.traditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.36TheU.K.modernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.37TheAsiaPacifichumaninsulinmarketshare,bycountry,byvalue,2013 FIG.38TheJapanesehumaninsulinmarketshare,bytype,byvalue,2013 FIG.39TheJapanesetraditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.40TheJapanesemodernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.41TheChinesehumaninsulinmarketshare,bytype,byvalue,2013 FIG.42TheChinesetraditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.43TheChinesemodernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.44TheIndianhumaninsulinmarketshare,bytype,byvalue,2013 FIG.45TheIndiantraditionalhumaninsulinmarketshare,bytype,byvalue,2013 FIG.46TheIndianmodernhumaninsulinmarketshare,bytype,byvalue,2013 FIG.47Competitivebenchmarkingofhumaninsulinmanufacturingcompanies FIG.48NovoNordisk’snetsalesandnetprofit,2011–2013(USDmillion) FIG.49EliLillyandCompany’srevenueandnetincome,2011–2013(USDmillion) FIG.50Sanofi’snetsalesandnetincome,2011–2013(USDmillion) FIG.51Biocon’srevenueandprofit,2012–2014(USDmillion) FIG.52TonghuaDongbaoPharmaceuticalCo.,Ltd.’stotalrevenueandnetincome,2011– 2013(USDmillion) FIG.53Wockhardt’srevenueandnetincome,2011–2013(USDmillion) FIG.54Julphar’ssalesandprofit,2011–2013(USDmillion) FIG.55Merck&Co.,Inc.’ssalesandnetincome,2011–2013(USDmillion) FIG.56Pfizer,Inc.’srevenueandnetincome,2011–2013(USDmillion) FIG.57Bristol-MyersSquibbCompany’stotalrevenueandnetearnings,2011–2013(USD million) FIG.58GlaxoSmithKlinePlc’sturnoverandprofit,2011–2013(USDmillion) 15 PersistenceMarketResearch

  16. HumanInsulinMarket-GlobalStudyonHumanInsulinIndustry:Asia PacifictoWitnessfastestGrowthby2020 AboutUs: PersistenceMarketResearchisaglobalmarketresearchfirmspecializing-syndicatedresearch,customresearch,andconsultingservices AtPersistenceMarketResearch(PMR),weareinthebusinessofacceleratingyourbusiness.Asafull- servicemarketresearchfirm,westandcommittedtobringingmoreaccuracyandspeedtoyourbusiness decisions.Fromready-to-purchasemarketresearchreportstocustomizedglobalresearchsolutions,our engagementmodelsarehighlyflexiblewithoutcompromisingonourdeep-seatedresearchvalues. Brieflystated,ourmissionistogiveyouaccesstoforecastsandtrendsanalysesthatputyouonthe pathto profitability. PMR’sServicesGoBeyondGleaningData MostenterprisesbelievethatITanddatabasesareenoughtomakeanaccuratedecision.Whilewedo notdisputethat,considerthis:Howlongdoesittaketomakeanaccurate decision?Westrivetodeliverbothevenwithdemandingdeadlines. andstrategicmillion-dollar ContactUs: AddieThomes 305Broadway 7thFloor,NewYorkCity, NY10007,UnitedStates, USA-CanadaTollFree:800-961-0353 Email:sales@persistencemarketresearch.com Web:http://www.persistencemarketresearch.com Twitter:https://twitter.com/addiethomes Blog:http://persistencemarketresearchblog.wordpress.com/ 16 PersistenceMarketResearch

More Related